Altimmune (ALT) Competitors

In the previous week, Altimmune and Altimmune both had 6 articles in the media. Altimmune's average media sentiment score of 0.15 beat Pharvaris' score of 0.00 indicating that Altimmune is being referred to more favorably in the media.

Pharvaris has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Altimmune's return on equity of -42.57% beat Pharvaris' return on equity.

Altimmune has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

Altimmune has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Pharvaris has a beta of -2.31, meaning that its share price is 331% less volatile than the broader market.

Altimmune currently has a consensus target price of $15.71, indicating a potential upside of 411.37%. Pharvaris has a consensus target price of $50.08, indicating a potential upside of 42.06%. Given Altimmune's higher possible upside, equities analysts clearly believe Altimmune is more favorable than Pharvaris.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Altimmune and Altimmune both had 6 articles in the media. Altimmune's average media sentiment score of 0.15 beat Sionna Therapeutics' score of -0.18 indicating that Altimmune is being referred to more favorably in the media.

Altimmune has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, meaning that its share price is 32% more volatile than the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Sionna Therapeutics' return on equity of -32.94% beat Altimmune's return on equity.

Altimmune presently has a consensus price target of $15.71, indicating a potential upside of 411.37%. Sionna Therapeutics has a consensus price target of $55.00, indicating a potential upside of 1,172.26%. Given Sionna Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Altimmune.

Sionna Therapeutics has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

78.1% of Altimmune shares are owned by institutional investors. 1.6% of Altimmune shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Hemab Therapeutics has a net margin of 0.00% compared to Altimmune's net margin of -214,860.98%. Hemab Therapeutics' return on equity of 0.00% beat Altimmune's return on equity.

78.1% of Altimmune shares are held by institutional investors. 1.6% of Altimmune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Hemab Therapeutics has lower revenue, but higher earnings than Altimmune. Altimmune is trading at a lower price-to-earnings ratio than Hemab Therapeutics, indicating that it is currently the more affordable of the two stocks.

In the previous week, Altimmune had 4 more articles in the media than Hemab Therapeutics. MarketBeat recorded 6 mentions for Altimmune and 2 mentions for Hemab Therapeutics. Hemab Therapeutics' average media sentiment score of 0.37 beat Altimmune's score of 0.15 indicating that Hemab Therapeutics is being referred to more favorably in the news media.

Altimmune currently has a consensus target price of $15.71, suggesting a potential upside of 411.37%. Hemab Therapeutics has a consensus target price of $48.00, suggesting a potential downside of 3.34%. Given Altimmune's higher probable upside, equities research analysts clearly believe Altimmune is more favorable than Hemab Therapeutics.

In the previous week, Zai Lab had 4 more articles in the media than Altimmune. MarketBeat recorded 10 mentions for Zai Lab and 6 mentions for Altimmune. Zai Lab's average media sentiment score of 0.56 beat Altimmune's score of 0.15 indicating that Zai Lab is being referred to more favorably in the media.

Zai Lab has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, Altimmune has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Zai Lab currently has a consensus target price of $40.20, suggesting a potential upside of 75.50%. Altimmune has a consensus target price of $15.71, suggesting a potential upside of 411.37%. Given Altimmune's higher probable upside, analysts clearly believe Altimmune is more favorable than Zai Lab.

Zai Lab has a net margin of -41.86% compared to Altimmune's net margin of -214,860.98%. Zai Lab's return on equity of -27.43% beat Altimmune's return on equity.

Altimmune has lower revenue, but higher earnings than Zai Lab. Zai Lab is trading at a lower price-to-earnings ratio than Altimmune, indicating that it is currently the more affordable of the two stocks.

41.7% of Zai Lab shares are owned by institutional investors. Comparatively, 78.1% of Altimmune shares are owned by institutional investors. 4.9% of Zai Lab shares are owned by insiders. Comparatively, 1.6% of Altimmune shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.